Abstract

Health sector faces a distress globally because of the scarcity of newer antibiotics against drug resistant pathogens. Innovations in developing new antibiotics is the solution to combat the drug resistant pathogens. This alarming situation requires advanced, potential and effective antibiotics. Secondary metabolite products from microbes remain as the main origin for many of the antibiotics in the market today and are also found to be promising till date. Out of the microbes, the major share of antibiotic production is reported by Actinomycetes, which are Gram positive, anaerobic, filamentous bacteria. They are currently being exploited through new approaches to improve the efficiency of commercially valuable antibiotics. Since natural environment stands a potential source of innovative and novel antimicrobials, this investigation was performed to test the potential of selected marine actinomycetes. Of the screened ones, Actinokineospora is potential enough to cease the growth of biofilm formation. This strain was identified by molecular characterization as Actinokineospora cibodasensis. It was selected to extract secondary metabolites by submerged fermentation and made to undergo further purification and structural analyses for the search of bioactive components. Presence of streptomycin like compound by Gas Chromatography Mass Spectrometry led to a breakthrough in the study which had been confined by High Performance Thin Layer Chromatography and Fourier Transform Infra-Red Spectroscopy techniques by comparing with standards. Gene expression studies showed that the selected strain can down regulate the genes in the formation of biofilm by the test organism Pseudomonas aeruginosa. The bioactive compound from Actinokineospora is an ecofriendly product along with a biofilm mitigating activity on medical devices. Rare actinomycetal isolate was able to produce the antibiotic which could apply on medical device to reduce the infections during the treatment. This antibiotic coating on life saving devices will provide the ultimate protection for patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.